Madden Sean P, Keilp John G, Wu Olivia, Corcoran Cheryl M, Girgis Ragy R, Vadhan Nehal P
Institute of Behavioral Science, Feinstein Institutes for Medical Research, Manhasset, NY, USA.
Department of Psychiatry, Columbia University Irving Medical Center and the New York State Psychiatric Institute, New York, NY, USA.
Cannabis. 2022 Feb 22;5(1):18-29. doi: 10.26828/cannabis/2022.01.003. eCollection 2022.
Some adverse cannabis effects are greater in individuals on the psychosis spectrum compared to healthy individuals. We have previously reported that smoked cannabis acutely worsened psychotic- like states and reduced cognitive performance selectively in cannabis users at clinical high-risk (CHR) for psychosis. The objective of the present study was to further investigate the acute effects of cannabis on cognition and reward processing in CHR cannabis users.
Six CHR cannabis users and six psychiatrically-healthy cannabis users comparable in intellectual, demographic, and cannabis use characteristics (including nontreatment-seeking status), participated in the study. Objective and subjective measures of cognition and cannabis reward, were completed before and after smoking half of an active (5.5% Δtetrahydrocannabinol [ΔTHC]) or half of a placebo (0.0% ΔTHC) cannabis cigarette, under randomized/double-blind conditions. Repeated measures ANOVA tested main effects of drug condition (active vs. placebo) and/or the drug condition × time (baseline vs. post-administration) interactions; groups were analyzed separately due to the small sample size.
CHR participants exhibited evidence of decreased objective response inhibition and aversive intoxication following active cannabis, relative to placebo. Psychomotor speed and cannabis-related attentional bias were also affected by cannabis intoxication. No such effects were observed in psychiatrically-healthy cannabis users.
These findings provide further preliminary evidence of a deleterious cognitive and reward- related response to cannabis in individuals with preexisting risk for psychosis.
与健康个体相比,处于精神病谱系的个体出现的一些大麻不良影响更为严重。我们之前曾报道,吸食大麻会使临床高危精神病患者(CHR)的类精神病状态急性恶化,并选择性降低其认知能力。本研究的目的是进一步调查大麻对CHR大麻使用者认知和奖赏加工的急性影响。
六名CHR大麻使用者和六名在智力、人口统计学及大麻使用特征(包括未寻求治疗状态)方面具有可比性的精神健康大麻使用者参与了本研究。在随机/双盲条件下,在吸食半支活性大麻卷烟(5.5% Δ-四氢大麻酚[ΔTHC])或半支安慰剂大麻卷烟(0.0% ΔTHC)之前和之后,完成对认知和大麻奖赏的客观及主观测量。重复测量方差分析检验药物条件(活性与安慰剂)的主效应和/或药物条件×时间(基线与给药后)的交互作用;由于样本量小,对各组分别进行分析。
与安慰剂相比,CHR参与者在吸食活性大麻后表现出客观反应抑制能力下降和厌恶中毒的迹象。精神运动速度和与大麻相关的注意偏向也受到大麻中毒的影响。在精神健康的大麻使用者中未观察到此类影响。
这些发现为已有精神病风险的个体对大麻产生有害的认知和奖赏相关反应提供了进一步的初步证据。